0000950170-24-026607.txt : 20240305 0000950170-24-026607.hdr.sgml : 20240305 20240305200007 ACCESSION NUMBER: 0000950170-24-026607 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rodino-Klapac Louise CENTRAL INDEX KEY: 0001836218 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 24723766 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: STE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 ownership.xml 4 X0508 4 2024-03-01 0000873303 Sarepta Therapeutics, Inc. SRPT 0001836218 Rodino-Klapac Louise 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 false true false false Head of R&D, CSO false Common Stock 2024-03-01 4 F false 778 126.19 D 65222 D Common Stock 2024-03-01 4 A false 6000 0 A 71222 D Stock Option (right to buy) 128.67 2024-03-01 4 A false 12500 0 A 2025-03-01 2034-03-01 Common Stock 12500 12500 D Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. Amount of Securities Beneficially Owned includes 249 shares purchased under the Company's registered Employee Stock Purchase Plan on February 29, 2024. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. /s/ Ryan Brown, as Attorney-in-Fact for Louise Rodino-Klapac 2024-03-05